Revised Organogenesis/Novartis Deal Ensures Sure-Footing For Vitrix Trials
This article was originally published in The Gray Sheet
Executive Summary
Organogenesis plans to enter pivotal clinical trials for its Vitrix living dermal replacement for deep diabetic foot ulcers this spring after amending a 1996 exclusive marketing agreement with Novartis covering Apligraf, announced Feb. 26.